These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1854 related items for PubMed ID: 12919886

  • 41. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK, VanOosten RL, Griffith TS.
    Cancer Res; 2006 Jan 01; 66(1):499-507. PubMed ID: 16397266
    [Abstract] [Full Text] [Related]

  • 42. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
    Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S.
    Cancer Res; 1999 Feb 01; 59(3):734-41. PubMed ID: 9973225
    [Abstract] [Full Text] [Related]

  • 43. ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation.
    Suzuki A, Kusakai G, Kishimoto A, Lu J, Ogura T, Esumi H.
    Oncogene; 2003 Sep 18; 22(40):6177-82. PubMed ID: 13679856
    [Abstract] [Full Text] [Related]

  • 44. Defining characteristics of Types I and II apoptotic cells in response to TRAIL.
    Ozören N, El-Deiry WS.
    Neoplasia; 2002 Sep 18; 4(6):551-7. PubMed ID: 12407450
    [Abstract] [Full Text] [Related]

  • 45. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.
    Aggarwal BB, Bhardwaj U, Takada Y.
    Vitam Horm; 2004 Sep 18; 67():453-83. PubMed ID: 15110190
    [Abstract] [Full Text] [Related]

  • 46. Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor {alpha}-related apoptosis-inducing ligand/anticancer drug combinations.
    Meurette O, Lefeuvre-Orfila L, Rebillard A, Lagadic-Gossmann D, Dimanche-Boitrel MT.
    Clin Cancer Res; 2005 Apr 15; 11(8):3075-83. PubMed ID: 15837763
    [Abstract] [Full Text] [Related]

  • 47. Failure of Bcl-2 to block mitochondrial dysfunction during TRAIL-induced apoptosis. Tumor necrosis-related apoptosis-inducing ligand.
    Kim EJ, Suliman A, Lam A, Srivastava RK.
    Int J Oncol; 2001 Jan 15; 18(1):187-94. PubMed ID: 11115558
    [Abstract] [Full Text] [Related]

  • 48. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells.
    Munshi A, McDonnell TJ, Meyn RE.
    Cancer Chemother Pharmacol; 2002 Jul 15; 50(1):46-52. PubMed ID: 12111111
    [Abstract] [Full Text] [Related]

  • 49. IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC.
    Ramaswamy M, Efimova EV, Martinez O, Mulherkar NU, Singh SP, Prabhakar BS.
    Oncogene; 2004 Aug 12; 23(36):6083-94. PubMed ID: 15208670
    [Abstract] [Full Text] [Related]

  • 50. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells.
    Hao JH, Yu M, Liu FT, Newland AC, Jia L.
    Cancer Res; 2004 May 15; 64(10):3607-16. PubMed ID: 15150119
    [Abstract] [Full Text] [Related]

  • 51. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
    Griffith TS, Fialkov JM, Scott DL, Azuhata T, Williams RD, Wall NR, Altieri DC, Sandler AD.
    Cancer Res; 2002 Jun 01; 62(11):3093-9. PubMed ID: 12036919
    [Abstract] [Full Text] [Related]

  • 52. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN.
    Cancer Res; 2001 Jan 15; 61(2):759-63. PubMed ID: 11212279
    [Abstract] [Full Text] [Related]

  • 53. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.
    Shankar S, Singh TR, Srivastava RK.
    Prostate; 2004 Sep 15; 61(1):35-49. PubMed ID: 15287092
    [Abstract] [Full Text] [Related]

  • 54. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I.
    Cancer Res; 2000 Aug 01; 60(15):4122-9. PubMed ID: 10945619
    [Abstract] [Full Text] [Related]

  • 55. The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels.
    Ruiz de Almodóvar C, Ruiz-Ruiz C, Muñoz-Pinedo C, Robledo G, López-Rivas A.
    Oncogene; 2001 Oct 25; 20(48):7128-33. PubMed ID: 11704839
    [Abstract] [Full Text] [Related]

  • 56. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
    Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N.
    Cancer Res; 2000 Aug 15; 60(16):4315-9. PubMed ID: 10969767
    [Abstract] [Full Text] [Related]

  • 57. A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents.
    Arizono Y, Yoshikawa H, Naganuma H, Hamada Y, Nakajima Y, Tasaka K.
    Br J Cancer; 2003 Jan 27; 88(2):298-306. PubMed ID: 12610517
    [Abstract] [Full Text] [Related]

  • 58. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC.
    Cancer Res; 2005 Jun 01; 65(11):4799-808. PubMed ID: 15930300
    [Abstract] [Full Text] [Related]

  • 59. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
    Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK.
    Int J Mol Med; 2005 Dec 01; 16(6):1125-38. PubMed ID: 16273296
    [Abstract] [Full Text] [Related]

  • 60. Impaired activation of caspases and prevention of mitochondrial dysfunction in the metastatic colon carcinoma CC531s-m2 cell line.
    Velthuis JH, Gavric Z, de Bont HJ, Nagelkerke JF.
    Biochem Pharmacol; 2005 Feb 01; 69(3):463-71. PubMed ID: 15652237
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 93.